Anthem Biosciences Limited Stock Price Today (NSE: ANTHEM)
Fundamental Score
Anthem Biosciences Limited Share Price — Live NSE/BSE Price, Fundamentals & Analysis
Anthem Biosciences Limited share price today is ₹755.60, up +0.21% on NSE/BSE as of 22 June 2026. Anthem Biosciences Limited (ANTHEM) is a Large-cap company in the Biotechnology sector with a market capitalisation of ₹37.01K (Cr). The 52-week high for ANTHEM share price is ₹873.50 and the 52-week low is ₹579.15. At a P/E ratio of 79.93x, ANTHEM is currently trading above its industry average P/E of 51.82x. The company has a Return on Equity (ROE) of 20.83% and a debt-to-equity ratio of 0.04.
Anthem Biosciences Limited Share Price Chart — NSE/BSE Historical Performance
Anthem Biosciences Limited share price chart: -1.61% return over the past month. 52-week high ₹873.50, 52-week low ₹579.15.
Anthem Biosciences Limited — Last 10 Trading Days
| Date | Open | High | Low | Close | Volume |
|---|---|---|---|---|---|
| ₹745.00 | ₹761.00 | ₹736.15 | ₹755.60 | 1.59L (Cr) | |
| ₹759.00 | ₹763.00 | ₹741.15 | ₹754.05 | 2.88L (Cr) | |
| ₹756.80 | ₹777.00 | ₹745.40 | ₹759.95 | 30.04L (Cr) | |
| ₹757.20 | ₹757.20 | ₹757.20 | ₹757.20 | 0.00 (Cr) | |
| ₹772.95 | ₹776.00 | ₹756.00 | ₹757.20 | 2.07L (Cr) | |
| ₹771.10 | ₹776.50 | ₹760.55 | ₹772.25 | 3.14L (Cr) | |
| ₹777.10 | ₹786.40 | ₹761.25 | ₹765.35 | 3.94L (Cr) | |
| ₹777.60 | ₹783.85 | ₹771.35 | ₹777.10 | 3.27L (Cr) | |
| ₹789.50 | ₹794.35 | ₹763.50 | ₹769.10 | 3.37L (Cr) | |
| ₹801.00 | ₹819.65 | ₹765.20 | ₹780.50 | 23.04L (Cr) |
Anthem Biosciences Limited — Last 12 Months Price History
| Month | Open | High | Low | Close | Change |
|---|---|---|---|---|---|
| ₹759.00 | ₹763.00 | ₹736.15 | ₹755.60 | -0.45% | |
| ₹766.20 | ₹825.65 | ₹745.40 | ₹759.95 | -0.82% | |
| ₹669.40 | ₹785.90 | ₹648.25 | ₹760.10 | +13.55% | |
| ₹653.05 | ₹697.70 | ₹608.30 | ₹656.25 | +0.49% | |
| ₹590.10 | ₹713.95 | ₹579.15 | ₹701.25 | +18.84% | |
| ₹649.50 | ₹660.00 | ₹580.65 | ₹599.30 | -7.73% | |
| ₹640.00 | ₹701.00 | ₹634.20 | ₹651.50 | +1.80% | |
| ₹709.70 | ₹715.50 | ₹620.00 | ₹634.70 | -10.57% | |
| ₹767.05 | ₹806.00 | ₹708.00 | ₹710.10 | -7.42% | |
| ₹826.00 | ₹873.50 | ₹758.20 | ₹761.20 | -7.85% | |
| ₹759.00 | ₹864.90 | ₹711.55 | ₹818.05 | +7.78% | |
| ₹723.05 | ₹801.85 | ₹701.90 | ₹759.15 | +4.99% |
AI Research Briefing
Powered by Gemini · 2026-04-09
Overvalued CRDMO play; priced for perfection, vulnerable to execution risks.
WHAT'S HAPPENING NOW (last 2-4 weeks)
No major catalysts found after live search. Anthem Biosciences closed its trading window on April 1, 2026, in anticipation of Q4 and full-year FY26 results. K. Ramakrishnan resigned as Other of the company, effective March 31, 2026.
CORE STORY (THE REAL GAME)
- Trading window closure signals upcoming Q4 FY26 results
- Strong EBITDA margins of 41.5%
- ₹1,260 crore from CRDMO business for the nine months ending December 31, 2025
- Q4 FY26 results beat/miss
- New order wins
- Significant capacity expansion announcements
- High P/E of 79.93x vs industry P/E of 51.82x
- Promoter holding decreased by 2.54%
- Revenue concentration risk
Promoter selling indicates potential concern.
India's biotech sector is targeting $300 billion by 2030, creating a tailwind.
Profit converting to cash; Free Cash Flow 5Y: ₹576.31 Cr
Focus on biosimilars and peptide development positions Anthem favorably. Expect 20% revenue growth for FY27.
Primary Thesis Risk
Inability to sustain high growth and margins will lead to valuation collapse.
For educational purposes only. Not investment advice. Consult a SEBI-registered advisor before investing.
Returns & Performance
Return on Equity (ROE)
Profit generated per ₹1 of shareholder equity
Return on Capital (ROCE)
Returns generated on total capital deployed
Oper. Profit Margin (5Y Avg)
Average operating profit margin over 5 years
Dividend Yield
Annual dividend as % of current share price
Anthem Biosciences Limited Valuation Check
Price to Earnings (P/E)
Share price ÷ earnings per share. Lower = cheaper
Industry Avg P/E
Average P/E of all peers in this sector
Market Capitalisation
Total market value of all outstanding shares
Growth Engine
Profit Growth (Quarterly YoY)
Net profit growth vs same quarter last year
Revenue Growth (Quarterly YoY)
Revenue growth vs same quarter last year
Revenue Growth (5-Year CAGR)
Compounded annual revenue growth over 5 years
EPS Growth (5-Year CAGR)
Earnings per share growth over 5 years
Net Profit Growth (5-Year CAGR)
Compounded annual net profit growth over 5 years
Balance Sheet Health
Debt to Equity Ratio
Total debt ÷ equity. Below 0.5 = financially healthy
Interest Coverage Ratio
EBIT ÷ interest expense. Above 2.5 = can pay interest comfortably
Free Cash Flow (5-Year Total)
Cash left after capex over 5 years. Positive = self-funded growth
Labels (e.g., "Excellent", "Good") are peer-based vs industry/sector averages — data-only, not advice
Anthem Biosciences Limited Fundamental Analysis & Valuation Benchmarking
Educational evaluation of ANTHEM across key market metrics for learning purposes.
Positive Indicators
10 factors identified
Strong Return on Equity (20.83%)
Observation: Efficient use of shareholders' capital generating superior returns.
Analysis: ROE >15% indicates strong profitability and effective management. This metric suggests the company can generate substantial returns on invested capital.
Excellent ROCE Performance (28.50%)
Observation: Superior returns on capital employed across business operations.
Analysis: ROCE >15% demonstrates efficient capital deployment and strong operational performance.
Strong Operating Margins (38.78%)
Observation: Healthy 5-year operating margins indicate pricing power and cost control.
Analysis: OPM >15% suggests operational efficiency and competitive advantages.
Consistent Growth Track Record (23.86% CAGR)
Observation: Strong 5-year sales compound annual growth rate.
Analysis: Consistent sales CAGR >12% demonstrates sustainable growth model.
Strong Profit Growth Track Record (37.27% CAGR)
Observation: Consistent 5-year profit compound annual growth rate.
Analysis: Profit CAGR >15% demonstrates scalable business model.
Conservative Debt Levels (D/E: 0.04)
Observation: Low leverage provides financial flexibility and reduced risk.
Analysis: Conservative debt structure offers resilience during economic downturns.
Strong Interest Coverage (63.42x)
Observation: Earnings comfortably cover interest obligations.
Analysis: Interest coverage >5x indicates low financial distress risk.
Strong Cash Generation (₹576.31 Cr over 5Y)
Observation: Healthy free cash flow generation supports growth and returns.
Analysis: Strong FCF provides flexibility for dividends, debt reduction, and growth investments.
Balanced Promoter Holding (74.69%)
Observation: Optimal balance between promoter control and public float.
Analysis: Promoter holding in 50-75% range provides management alignment.
Zero Share Pledging Risk
Observation: No promoter shares pledged as collateral.
Analysis: Absence of share pledging eliminates potential forced-selling pressure.
Risk Factors
4 factors identified
Premium Valuation Risk (P/E: 79.93x)
Observation: High valuation multiples may limit upside potential.
Analysis: Elevated P/E ratios require strong growth execution to justify current valuations.
Weak Earnings Growth (-40.74% CAGR)
Observation: Below-average 5-year EPS growth performance.
Analysis: Low EPS growth may not keep pace with inflation.
Limited Institutional Interest (FII+DII: 8.87%)
Observation: Low institutional participation may affect liquidity.
Analysis: Limited institutional interest may indicate size constraints or visibility issues.
No Dividend Distribution
Observation: Company does not currently pay dividends to shareholders.
Analysis: Zero dividend yield may indicate growth reinvestment focus or cash flow constraints.
Anthem Biosciences Limited vs Biotechnology Peers
Peer Comparison - Biotechnology
Compare Anthem Biosciences Limited with 4 other companies in the same sector
| Company Info | Fundamental | Valuation | Profitability | Financial Health | Growth | Dividend | ||||
|---|---|---|---|---|---|---|---|---|---|---|
Company Company name | Score Bull Run comprehensive fundamental score based on 20+ metrics | Price Current trading price of the stock | Market Cap Total value of all shares in the market | P/E Price per share divided by earnings per share | ROE Net income divided by shareholder equity | ROCE Earnings before interest and tax divided by capital employed | Debt/Eq Total debt divided by total equity | Profit 5Y Average annual profit growth over 5 years | Sales 5Y Average annual sales growth over 5 years | Dividend Annual dividend per share divided by price per share |
Anthem Biosciences LimitedAnthem Bioscien...Selected✓ ANTHEM • 544449 | 63.7/100 | ₹755.60₹756 | ₹37009.24₹37009.24 | 79.93Average 79.9 Average | 20.83%Excellent 20.83% Excellent | 28.50%Excellent 28.50% Excellent | 0.04Excellent 0.0 Excellent | 37.27%Excellent 37.27% Excellent | 23.86%Excellent 23.86% Excellent | 0.00% |
Advanced Enzyme Technologies LtdAdvanced Enzyme... ADVENZYMES • 540025 | 63.6/100 | ₹371.75₹372 | ₹3493.23₹3493.23 | 23.70Average 23.7 Average | 9.54%Poor 9.54% Poor | 13.11%Average 13.11% Average | 0.02Excellent 0.0 Excellent | 0.26%Average 0.26% Average | 7.48%Good 7.48% Good | 1.66% |
Genesis IBRC India LtdGenesis IBRC In... GENESIS • 514336 | 25/100 | ₹116.90₹117 | ₹177.38₹177.38 | — — | 51.62%Excellent 51.62% Excellent | 51.62%Excellent 51.62% Excellent | 0.00Excellent 0.0 Excellent | 105.89%Excellent 105.89% Excellent | — — | 0.00% |
Vivo Bio Tech LtdVivo Bio Tech L... VIVOBIOT • 511509 | 16/100 | ₹26.87₹27 | ₹68.05₹68.05 | 16.64Average 16.6 Average | 5.68%Poor 5.68% Poor | 9.04%Poor 9.04% Poor | 0.58Good 0.6 Good | -3.27%Poor -3.27% Poor | -3.35%Poor -3.35% Poor | 0.00% |
Genomic Valley Biotech LtdGenomic Valley ... GVBL • 539206 | 24.6/100 | ₹24.25₹24 | ₹8.81₹8.81 | 88.14Average 88.1 Average | 9.68%Poor 9.68% Poor | 11.83%Average 11.83% Average | 0.00Excellent 0.0 Excellent | 4.42%Average 4.42% Average | -0.24%Poor -0.24% Poor | 0.00% |
Top Biotechnology Stocks
View all →By Bull Run Score
By Return on Equity
By Market Cap
Anthem Biosciences Limited PE Ratio History
Historical price-to-earnings ratio for ANTHEM — last 5 years
| Year | EPS (₹) | Price (₹) | P/E Ratio |
|---|---|---|---|
| FY 2025 | ₹8.04 | ₹651.50 | 81.1x |
P/E = year-end price ÷ diluted EPS from annual filings. Source: NSE/BSE via Bull Run.
Anthem Biosciences Limited Dividend History
Annual cash dividends paid by ANTHEM — dividend yield N/A
| Financial Year | Dividends Paid (₹ Cr) |
|---|---|
| FY 2022 | ₹0.00 Cr |
Cash dividends from annual cash flow statements. Past dividends do not guarantee future payments. Not investment advice.
Anthem Biosciences Limited Quarterly Performance
Latest quarterly metrics for ANTHEM — revenue growth and profit growth vs same quarter last year
Revenue Growth (YoY)
4.78%
Latest quarter vs same quarter previous year
Net Profit Growth (YoY)
7.10%
Latest quarter net profit vs same quarter previous year
5-Year Revenue CAGR
23.86%
Compounded annual revenue growth over 5 years
5-Year Profit CAGR
37.27%
Compounded annual net profit growth over 5 years
Anthem Biosciences Limited Technical Indicators
SMA 50, SMA 200, RSI and volume signals for ANTHEM — calculated from daily price history
Momentum is balanced — neither overbought nor oversold.
Technical indicators are for educational purposes only. Not investment advice.
Anthem Biosciences Limited Financial Statements
Annual income statement, balance sheet and cash flow for Anthem Biosciences Limited (ANTHEM) — sourced from NSE/BSE filings.
Loading Financial Statements...
Fetching financial data for Anthem Biosciences Limited
About ANTHEM (Anthem Biosciences Limited)
Anthem Biosciences Limited is a dynamic and innovative biotechnology company dedicated to accelerating scientific discovery and delivering impactful solutions across the pharmaceut...ical and life sciences industries. At the core of Anthem's operations lies a deep commitment to fostering collaborative partnerships with clients, offering a comprehensive suite of services designed to streamline the drug development process from inception to commercialization. Anthem distinguishes itself through its cutting-edge technological capabilities, seamlessly integrating advanced analytical techniques, bioinformatics, and process development strategies to optimize research outcomes and drive efficiency. The company's unwavering focus on quality, combined with its agile and client-centric approach, positions it as a trusted partner for organizations seeking to navigate the complexities of modern drug development and biomanufacturing. Anthem Biosciences operates through a dual-faceted approach, encompassing both comprehensive CRDMO services and the production of specialized ingredients. The CRDMO arm provides end-to-end support for both novel chemical entities (NCEs) and novel biological entities (NBEs), guiding projects through every stage of the pipeline. From the initial spark of target identification and proof-of-concept studies to rigorous preclinical development and the production of development batches for clinical trials, Anthem offers a seamless and integrated experience. This holistic approach allows clients to benefit from streamlined communication, reduced timelines, and enhanced control over the entire development process. Moreover, Anthem's expertise in specialty ingredient manufacturing ensures the availability of high-quality raw materials and key components critical for successful drug formulation and production. Beyond its core service offerings, Anthem Biosciences is driven by a vision to push the boundaries of biotechnological innovation. The company fosters a culture of scientific excellence, attracting top talent and investing heavily in research and development. Anthem's commitment to sustainability is evident in its environmentally conscious practices and dedication to responsible manufacturing. By embracing cutting-edge technologies and fostering a collaborative ecosystem, Anthem Biosciences is poised to play a significant role in shaping the future of healthcare. With a steadfast commitment to delivering exceptional value and driving scientific breakthroughs, Anthem Biosciences is truly at the forefront of the biotechnology revolution.
Company Details
Key Leadership
Latest News
ANTHEM Share Price: Frequently Asked Questions
What is the current share price of Anthem Biosciences Limited?
Anthem Biosciences Limited (ANTHEM) trades at ₹755.60 on NSE and BSE. Market cap ₹37.01K (Cr). Educational data only.
What is the P/E ratio of Anthem Biosciences Limited?
Anthem Biosciences Limited has a P/E of 79.93x vs industry average 51.82x.
What is the Bull Run score for Anthem Biosciences Limited?
Anthem Biosciences Limited has a Bull Run score of 63.7/100 based on 25+ financial parameters.
Does Anthem Biosciences Limited pay dividends?
Anthem Biosciences Limited has a dividend yield of 0.00%. Past dividends don't guarantee future payments.
What is the ROE of Anthem Biosciences Limited?
Anthem Biosciences Limited has ROE of 20.83%. Higher ROE indicates better use of shareholder equity.
What is the debt-to-equity ratio of Anthem Biosciences Limited?
Anthem Biosciences Limited has debt-to-equity of 0.04.
Is Anthem Biosciences Limited a good investment?
Bull Run gives Anthem Biosciences Limited a score of 63.7/100. This is not investment advice — consult a SEBI-registered advisor.